Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

As Brexit Looms, Novartis and Roche Stockpile Medicines in Case of No-Deal

As the United Kingdom nears closer to exiting the European Union without a deal, drug manufacturers such as Novartis are preparing contingencies for how they will continue to provide medications – many of them life-saving – for patients in the U.K.

Read More »

More blood pressure drugs may have shortages after recalls: FDA

Additional shortages of blood pressure drugs in the United States are possible following recent recalls related to traces of a probable carcinogen found in some versions a particular class of hypertension medicines, the U.S. Food and Drug Administration said.

Read More »

Not-for-profit to offer 20 generic drugs in 2019 to alleviate shortages

A new not-for-profit supplier of generic drugs formed by a consortium of hospitals systems expects to be able to provide about 20 products during 2019 to alleviate shortages of medicines used during surgeries and to treat life-threatening conditions, such as septic shock.

Read More »

European Commission Approves Blincyto In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia

Amgen announced that the European Commission approved an expanded indication for Blincyto monotherapy to include adult patients with Philadelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease greater than or equal to 0.1 percent.

Read More »

U.S. insulin costs per patient nearly doubled from 2012 to 2016: study

The cost of insulin for treating type 1 diabetes in the United States nearly doubled over a five-year period, underscoring a national outcry over rising drug prices, according to a new analysis shared with Reuters.

Read More »

Imbruvica fails to meet pancreatic cancer study goal

AbbVie Inc.’s blockbuster cancer treatment Imbruvica in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.

Read More »

Samsung Bioepis biosimilar to Roche’s Herceptin wins FDA nod

The U.S. Food and Drug Administration approved a biosimilar to Roche Holding AG’s blockbuster breast cancer treatment Herceptin.

Read More »

Lilly’s cancer therapy Lartruvo fails study, shares drop

Eli Lilly’s shares fell after the cancer treatment Lartruvo – approved on an accelerated basis in 2016 – failed to improve patient survival in a long-term study and will no longer be prescribed.

Read More »

FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy for initial treatment of metastatic non-squamous non-small cell lung cancer

Roche announced that the U.S. Food and Drug Administration accepted the company’s supplemental Biologics License Application (sBLA) for Tecentriq in combination with Abraxane and carboplatin for the initial treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumor aberrations.

Read More »

House Oversight Committee Takes on Pharma Industry

The House Committee on Oversight and Reform launched an investigation into prescription drug pricing practices.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom